Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3912-3920
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3912
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3912
Table 1 Study population characteristics n (%)
n | 358 |
Gender (M/F) | 281 (78.5)/77 (21.5) |
Age at LT (yr, mean ± SD) | 52 ± 9 |
Donor age (yr, mean ± SD) | 53 ± 17 |
HCV Genotype | |
1 | 212 (59.2) |
2 | 48 (13.4) |
3 | 57 (15.9) |
4 | 41 (11.5) |
Immunosuppression | |
Cyclosporine | 269 (75.1) |
Tacrolimus | 83 (23.2) |
Other regimens | 6 (1.7) |
Antiviral therapy after LT | |
Treated | 150 (41.9) |
Untreated | 208 (58.1) |
Table 2 Characteristics of treated and untreated patients n (%)
Treated | Untreated | χ2/Mann Whitney-U | |
n | 150 | 208 | |
Gender (M/F) | 120/30 | 161/47 | P = NS |
Age at LT (yr, mean ± SD) | 52 ± 8 | 52 ± 9 | P = NS |
Donor age (yr, mean ± SD) | 53 ± 17 | 53 ± 17 | P = NS |
HCV genotype | P = NS | ||
1 | 97 (64.7) | 115 (55.3) | |
2 | 16 (10.7) | 35 (16.8) | |
3 | 25 (16.6) | 35 (16.8) | |
4 | 12 (8.0) | 23 (11.1) | |
Immunosuppression | P = 0.011 | ||
Cyclosporine | 102 (68.0) | 165 (79.3) | |
Tacrolimus | 46 (30.7) | 39 (18.8) | |
Other regimens | 2 (1.3) | 4 (1.9) |
Table 3 Characteristics of patients divided by groups
Group | A | B | C | D | E | χ2/Kruskall Wallis |
SVR | NR | Mild recurrence | Too sick | Comorbidity | ||
n | 63 | 87 | 73 | 35 | 100 | |
Gender (M/F) | 47/16 | 73/14 | 63/10 | 20/15 | 78/22 | P = 0.007 |
Age at LT (yr, mean ± SD) | 52 ± 8 | 52 ± 9 | 53 ± 8 | 52 ± 9 | 51 ± 9 | P = NS |
Donor age (yr, mean ± SD) | 49 ± 17 | 56 ± 15 | 48 ± 17 | 59 ± 15 | 55 ± 17 | P = 0.001 |
HCV genotype | P = NS | |||||
1 | 37 | 60 | 45 | 16 | 44 | |
2 | 7 | 6 | 9 | 3 | 13 | |
3 | 9 | 13 | 6 | 5 | 14 | |
4 | 8 | 5 | 7 | 1 | 10 | |
Immunosuppression | 48 | 55 | 54 | 24 | 83 | P = NS |
Cyclosporine | 14 | 31 | 16 | 10 | 13 | |
Tacrolimus | 1 | 1 | 3 | 1 | 4 | |
Other regimens | ||||||
Time between treatment start and LT [mo, median (min-max)] | 20 (1-148) | 16 (1-117) | P = NS | |||
Treatment Length [mo, median (min-max)] | 11 (1-61) | 6 (1-63) | P = 0.010 |
Table 4 Causes of death
Group | A | B | C | D | E |
SVR | NR | Mild recurrence | Too sick | Comorbidity | |
n | 63 | 87 | 73 | 35 | 100 |
No. of deaths at 10 yr after LT, n (%) | 7 (11.1) | 35 (40.2) | 6 (8.2) | 35 (100) | 20 (20) |
Liver related, n (%) | 2 (28.6) | 22 (62.9) | 3 (50) | 11 (31.4) | 10 (50) |
HCV recurrence | 1 | 17 | 2 | 3 | 1 |
HCC | 1 | 4 | 1 | 1 | 8 |
Primary non function | 0 | 0 | 0 | 6 | 0 |
Other liver-related | 0 | 1 | 0 | 1 | 1 |
Non liver-related, n (%) | 5 (71.4) | 13 (37.1) | 3 (50) | 24 (68.6) | 10 (50) |
Cardiac | 1 | 0 | 0 | 0 | 0 |
Renal | 0 | 2 | 0 | 0 | 0 |
Cancer | 0 | 1 | 0 | 3 | 6 |
Infection | 0 | 6 | 1 | 10 | 3 |
Vascular | 0 | 0 | 1 | 0 | 0 |
Other comorbidity | 4 | 4 | 1 | 11 | 1 |
- Citation: Gitto S, Belli LS, Vukotic R, Lorenzini S, Airoldi A, Cicero AFG, Vangeli M, Brodosi L, Panno AM, Di Donato R, Cescon M, Grazi GL, De Carlis L, Pinna AD, Bernardi M, Andreone P. Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. World J Gastroenterol 2015; 21(13): 3912-3920
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3912.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3912